| INTRODUCTIONApproximately 5% of all human cancers are caused by HPV infection, resulting in more than 600 000 new cases per year worldwide. 1 The cervix, penis, vulva, vagina, anus, and oropharynx are among the tissues for which the International Agency for Research on Cancer has acknowledged a direct causal correlation between HPV and disease, although the strength of the correlation does vary. 2 Therefore, HPV is considered the most important oncogenic virus affecting humans and the primary cause of uterine cervical cancer. 2 Among the high-risk genotypes for neoplastic transformation, HPV16 and HPV18 show the most biologically aggressive behavior and are the main contributors to HPV-related carcinogenesis. 3 However, other high-risk genotypes are also involved in cancer transformation, with their contribution varying with anatomic region. In the uterine cervix, the contribution of non-HPV16/HPV18 genotypes to HPV-related tumor genesis is approximately 30% (Fig. 1), whereas in the anal, vulvovaginal, penile, and oropharyngeal areas, their contribution is less relevant. 4 Two available vaccines, one of which is bivalent against HPV16 and HPV18 (2vHPV) and the other quadrivalent Efficacy data come from a pivotal trial, which was conducted among women aged 16-26 years randomly assigned to receive either the 9vHPV or the quadrivalent HPV (4vHPV) vaccine. The 9vHPV vaccine was shown to have potential benefits as compared with 4vHPV, increasing the overall estimated rate of prevention to 90% for cervical cancer and up to 80% for precancerous cervical lesions. For all other HPVrelated pre-invasive and invasive lesions, 9vHPV showed potentially greater disease reduction, depending on the anatomic region examined. Thus, the 9vHPV vaccine shows clinical potential for the prevention of HPV-related diseases in both sexes.Future adoption of 9vHPV will depend on factors including market price, costeffectiveness data, use of a two-dose schedule, and safety and efficacy monitoring in real-life programs.